The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...
Zacks.com on MSN9d
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial CancerGSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...
GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...
GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...
GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...
The European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for ...
GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line ...
The tolerability and safety profile for Jemperli combined with carboplatin-paclitaxel was consistent with the known safety profiles of the individual agents. Endometrial cancer originates in the ...
London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback